<DOC>
	<DOC>NCT00975650</DOC>
	<brief_summary>This clinical trial is being performed to compare the pharmacokinetic profile of testosterone after repeated intra-nasal administration of products of different strengths in subjects with hypogonadism.</brief_summary>
	<brief_title>Efficacy and Tolerability of an Intra-Nasal Testosterone Product</brief_title>
	<detailed_description />
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>Men with primary or secondary hypogonadism and a serum morning (0900 h ± 30 minutes) testosterone levels &gt;100 ng/dl and ≤ 300 ng/dL. Normal Otolaryngological nasal endoscopy examination. Normal prostate examination (no palpable prostatic mass), and serum PSA ≤ 4.0 ng/mL. Current treatment with other androgens (i.e. DHEA), anabolic steroids or other sex hormones Treatment with Estrogens, GnRH antagonists, or Growth Hormone within previous 12 months History of nasal surgery, specifically turbinoplasty, septoplasty, rhinoplasty, or sinus surgery. History of nasal disorders (e.g. polyposis, recurrent epistaxis ( &gt; 1 nose bleed per month, abuse of nasal decongestants) or sleep apnea.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Primary Hypogonadism</keyword>
	<keyword>Secondary Hypogonadism</keyword>
</DOC>